Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Completed
CT.gov ID
NCT03794284
Collaborator
Prince of Wales Hospital, Shatin, Hong Kong (Other)
46
1
41
1.1

Study Details

Study Description

Brief Summary

The study will use the VereMTB tool for rapid diagnosis of TB or non-tuberculous mycobacterium (NTM) pulmonary infections in hospitalised patients, with positive results in acid-fast bacilli smears, which are emerging in many regions of the world.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: VereMTB

Detailed Description

Delay in diagnosis and treatment of tuberculosis was common in hospitalised patients all around the world, and was associated with poorer outcomes, including respiratory failure and mortality. Rapid and accurate tools for diagnosis of TB is of great importance in initial treatment and for better treatment outcomes. Other than TB, non-tuberculous mycobacterium (NTM) pulmonary infections are emerging in many regions of the world. These bacterium are more common to be found in respiratory specimens than MTB. With similar clinical presentation of NTM pulmonary infections and pulmonary TB, misdiagnosis of NTM pulmonary infections to pulmonary TB would lead to unnecessary intake of anti-TB medications and delay of the initiation of corresponding treatment.

This test aims to detect MTB as well differentiate the NTM species involved in pulmonary infections simultaneously using VereMTB.

Study Design

Study Type:
Observational
Actual Enrollment :
46 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Performance of a Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium Tuberculosis and Non-tuberculous Mycobacterium Species in Smear-positive Pulmonary Clinical Specimens
Actual Study Start Date :
Feb 28, 2019
Actual Primary Completion Date :
Jul 31, 2022
Actual Study Completion Date :
Jul 31, 2022

Outcome Measures

Primary Outcome Measures

  1. diagnostic test correlation [6 months from the date of first recruitment]

    Sensitivity, specificity, positive predictive value, and negative predictive value, will be calculated to determine accuracy of VereMTB, in diagnosing MTB and NTM

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age 18 or older

  2. One or more symptoms compatible with mycobacterial pulmonary infections, including fever, cough, sputum production,hemoptysis dyspnea, chest pain and weight loss

  3. One or more sputum samples with positive AFB smear

Exclusion Criteria:
  1. Receiving anti-mycobacterial treatment for more than one week

  2. Refusal to consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Prince of Wales Hospital Sha Tin Hong Kong

Sponsors and Collaborators

  • Chinese University of Hong Kong
  • Prince of Wales Hospital, Shatin, Hong Kong

Investigators

  • Principal Investigator: Chung Yan Grace Lui, Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Grace Lui, Assistant Professor and Head, Division of Infectious Diseases, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT03794284
Other Study ID Numbers:
  • VereMTB_v2_24_10_2018
First Posted:
Jan 7, 2019
Last Update Posted:
Aug 9, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 9, 2022